Enacitib (Enasidenib), generic Idhifa is a prescription medicine used to treat patients with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatments. Enasidenib works by helping patient’s bone marrow grow normal blood cells so patient will need fewer blood transfusions.